A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC. Issue 3 (21st December 2020)

• Record Type: Journal Article
• Authors: Cabrera, Roniel; Singal, Amit G.; Colombo, Massimo; Kelley, R. Kate; Lee, Hannah; Mospan, Andrea R.; Meyer, Tim; Newell, Pippa; Parikh, Neehar D.; Sangro, Bruno; Reddy, K. Rajender; Watkins, Stephanie; Zink, Richard C.; Di Bisceglie, Adrian M.
• Other Names: Agrawal Saurabh investigator.; Anty Rodolphe investigator.; Babicky Michele investigator.; Berg Thomas investigator.; Bernstein David investigator.; Best Jan investigator.; Borg Brian investigator.; Brown Robert investigator.; Bruno Savino investigator.; Cabrera Roniel investigator.; Calleja Jose investigator.; Camma Calogero investigator.; Chak Erik investigator.; Curry Michael investigator.; Delgado Manuel investigator.; Eswaran Sheila investigator.; Galati Joseph investigator.; Galle Peter investigator.; Garcia‐Saenz‐de‐Sicilia Mauricio investigator.; Adel Ghali Maged investigator.; Hayashi Paul investigator.; Iqbal Syma investigator.; Jones Patricia investigator.; Kelley Katie investigator.; Koch David investigator.; Kulik Laura investigator.; Kwo Paul investigator.; Landis Charles investigator.; Lee Hannah investigator.; Lucey Michael investigator.; Mangia Alessandra investigator.; Mantry Parvez investigator.; Mena Edward investigator.; Modi Apurva investigator.; Olivera‐Martinez Marco investigator.; Overton Lindsay investigator.; Parikh Neehar investigator.; Park James investigator.; Pelletier Shawn investigator.; Pillai Anjana investigator.; Pol Stanislas investigator.; Reddy K. Rajender investigator.; Regenstein Fredric investigator.; Rich Nicole investigator.; Richart John investigator.; Roberts Lewis investigator.; Roderburg Christoph investigator.; Rodriguez de Lope Carlos investigator.; Romero Manuel investigator.; Rubin Angel investigator.; Rustgi Vinod investigator.; Salgia Reena investigator.; Sangiovanni Angelo investigator.; Sangro Bruno investigator.; Scanga Andrew investigator.; Schmeltzer Paul investigator.; Shiffman Mitchell investigator.; Shrestha Roshan investigator.; Smith Coleman investigator.; Stine Jonathan investigator.; Sulkowski Mark investigator.; Tanaka Tomohiro investigator.; Thuluvath Paul investigator.; Trautwein Christian investigator.; Verna Elizabeth investigator.; Vogel Arndt investigator.; Wedd Joel investigator.; Weiss L. Michael investigator.; Wong Mark investigator.; Zeuzem Stefan investigator.;
• Is Part Of: Hepatology communications. Volume 5:Issue 3(2021)
• Page Start: 538
• Page End: 547
• Publication Date: 2020-12-21
• Subjects: Hepatology -- Periodicals; Liver -- Diseases -- Periodicals; Liver Diseases; Gastroenterology; Periodicals; Fulltext; Internet Resources; Periodicals; 616.36
• DOI: 10.1002/hep4.1652
• Languages: English
• ISSNs: 2471-254X

Abstract

Abstract : This study describes the design of the TARGET‐hepatocellular carcinoma (HCC) cohort and descriptive characteristics of the patient population at diagnosis among those who were enrolled in the cohort across academic and community clinical centers. TARGET‐HCC is a 5‐year, longitudinal, observational cohort of patients with HCC receiving care in usual clinical practice. Redacted clinical information, obtained from medical records, captures the natural history and management of the disease, including the safety and efficacy of treatment interventions used in usual clinical practice. Patients can complete patient‐reported outcome measures and provide biological specimens for future translational studies. The TARGET‐HCC study includes adults with histologic, cytologic, or radiologic diagnosis of HCC from academic and community centers in both the United States and Europe. A total of 1, 841 participants were enrolled between January 9, 2017, and July 23, 2019, at 67 sites in the United States and Europe. To date, the most common liver disease etiology in the cohort continues to be hepatitis C, although nearly half had a nonviral etiology, including alcohol‐related liver disease or nonalcoholic steatohepatitis. Most included patients were diagnosed at an early stage (Barcelona Clinic Liver Cancer Stage [BCLC] 0/A), but only approximately one third underwent curative treatment. Systemic therapy has been used in 7.3% of enrolled patients, including 45.7% of those with BCLC stage C tumors. Conclusion: Overall, the TARGET‐HCC cohort allows for the assessment of patient characteristics and investigation of new treatment paradigms and sequencing with existing agents as well as novel regimens for HCC. Abstract : TARGET‐HCC is a 5‐year, longitudinal, observational cohort of patients with hepatocellular carcinoma receiving care in usual clinical practice. The objective of this manuscript is to describe the design of the TARGET‐HCC cohort and descriptive characteristics of the patient population at diagnosis across academic and community clinical centers.